<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180506039542N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-06-29</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effects of exercise in major depression disorders</public_title>
      <acronym></acronym>
      <scientific_title>Can exercise enhance the positive effects of sertraline in patients with major depressive disorders? A randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2015-04-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/30959</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants were randomly assigned to either control or study group with a 1:1 allocation ratio by TENALEA, which is an online, central randomization service using permuted blocks of random sizes. 
 In order to confirm allocation concealment, the randomization code was not released by the service until the patient had been enrolled in the study, which happened after all baseline measurements have been completed, Blinding description: Since exercise is an overt behavior, there was not the possibility of blinding the participants and care providers. Thus, only those assessing outcomes were blinded.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Major depressive disorder.</hc_freetext>
      <i_freetext>Intervention 1: Control group: The control group were patients diagnosed with major depression on sertraline prior to this study with a dosage range of 50 to 150 mg daily. They continued to receive sertraline for 8 weeks (during the study). Intervention 2: Intervention group: Patients assigned to the test group were asked to perform regular exercises, 60 minutes a session, three times a week, under the supervision of a registered trainer for a total duration of 8 weeks. Physical activity was scheduled as aerobic, stretching and strengthening  exercises. Patients were asked to do 15 minutes of warm up, and 40 minutes of stretching and strengthening exercises followed by 5 minutes of cooling down with low intensity activities. Patients enrolled in the test group received sertraline prior to this study with a dosage range of 50 to 150 mg daily which continued during the study.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Bita Tavana</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.7, Jalal-e-Al-e-Ahmad Highway. Sports and Exercise Research Center, the Tehran University of Medical Sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14395-578</zip>
        <telephone>+98 21 8863 0227</telephone>
        <email>b-tavana@farabi.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Bita Tavana</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.7, Jalal-e-Al-e-Ahmad Highway. Sports and Exercise Research Center, the Tehran University of Medical Sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>14395-578</zip>
        <telephone>+98 21 8863 0227</telephone>
        <email>b-tavana@farabi.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients were diagnosed with major depression based on DSM-V criteria
All the patients were on sertraline prior to study
Patients were healthy and were able to execute regular exercise</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who had psychosis
Patients who had suicidal actions or thoughts
Patients who had self-mutilation
Patients who had chronic diseases associated with vital organs such as heart, lungs, and kidneys
Patients who had bone and soft tissue disorders which made it impossible to comply with the exercise schedule</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>V</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Mental and behavioral disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Behavior</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: The control group were patients diagnosed with major depression on sertraline prior to this study with a dosage range of 50 to 150 mg daily. They continued to receive sertraline for 8 weeks (during the study).</i_keyword>
      <i_keyword>Intervention group: Patients assigned to the test group were asked to perform regular exercises, 60 minutes a session, three times a week, under the supervision of a registered trainer for a total duration of 8 weeks. Physical activity was scheduled as aerobic, stretching and strengthening  exercises. Patients were asked to do 15 minutes of warm up, and 40 minutes of stretching and strengthening exercises followed by 5 minutes of cooling down with low intensity activities. Patients enrolled in the test group received sertraline prior to this study with a dosage range of 50 to 150 mg daily which continued during the study.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Depression score in Hamilton depression scale. Timepoint: At the beginning of the study (prior to initiation of the intervention) and eight weeks after starting of the exercise. Method of measurement: Hamilton depression scale.</prim_outcome>
      <prim_outcome>Depression scores in Beck depression inventory. Timepoint: At the beginning of the study (prior to initiation of the intervention) and eight weeks after starting of the exercise. Method of measurement: Beck depression inventory.</prim_outcome>
      <prim_outcome>Anxiety scores in Hamilton anxiety scale. Timepoint: At the beginning of the study (prior to initiation of the intervention) and eight weeks after starting of the exercise. Method of measurement: Hamilton anxiety scale.</prim_outcome>
      <prim_outcome>Anxiety scores in Beck anxiety inventory. Timepoint: At the beginning of the study (prior to initiation of the intervention) and eight weeks after starting of the exercise. Method of measurement: Beck anxiety inventory.</prim_outcome>
      <prim_outcome>Sleep quality index in Pittsburg sleep quality index. Timepoint: At the beginning of the study (prior to initiation of the intervention) and eight weeks after starting of the exercise. Method of measurement: Pittsburg sleep quality index.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Body mass index. Timepoint: At the beginning of the study (prior to initiation of the intervention) and eight weeks after starting of the exercise. Method of measurement: The body weight (kilograms) divided by the square of the body height (square meters).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-05-03</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for Research and Technology, 6th floor, Central Building of Tehran Universtiy of Medical Sciences, Corner of Qods Street, Keshavarz Blvd. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
